Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
October 10 2024 - 8:30AM
Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused
on addressing significant unmet needs of women worldwide with a
broad portfolio of in-office, accessible, and innovative
therapeutic and diagnostic products, announces that the Company
will be exhibiting at the American Society of Reproductive
Medicine’s (ASRM) 2024 Scientific Congress and Expo, being held
October 19-23 in Denver, Colorado. The Company will be showcasing
its solutions at booth #243.
Femasys’ FemaSeed® and FemVue® products will be
featured in ASRM’s Knowledge through Engagement and Education
Program for Residents (KEEPR) program. The in-person resident
program, being held October 23, will offer exclusive evidence-based
and bias-free learning for residents. Through interactive
workshops, skill-building activities, and advanced independent
study, residents will explore important and trending topics with
experts, including working with products that impact and preserve
reproduction.
Additionally, Femasys VP of Education and Global
Training, Andrew Young was elected chairman of the ASRM Corporate
Member Council, as voted by peers in reproductive medicine and
corporate memberships. The Corporate Member Council is a
partnership between ASRM officers, directors, and corporate members
and is designed to facilitate open and ongoing dialogue between the
two to drive education and innovation, which will serve to enhance
the practice of reproductive medicine. Young will begin his
one-year term at the close of the ASRM event. Femasys’ CEO, Kathy
Lee-Sepsick is also a member of the Council.
Lee-Sepsick commented, “The ASRM is a key
advocate for reproductive medicine and its annual event an
important venue for us to demonstrate the value of our products to
healthcare practitioners and thought leaders in attendance. We are
grateful that the organizers have recognized that FemaSeed and
FemVue represent part of the future of reproductive medicine, and
we are eager to engage with young physicians as they learn about
the advantages and are trained on the use of our products. We are
particularly proud of Andrew Young for being elected as chair of
the ASRM Corporate Member Council and look forward to our continued
collaboration with ASRM as we advance our U.S. commercialization
efforts for FemaSeed and FemVue.”
To learn more about ASRM 2024, visit the
organization’s website.
About Femasys
Femasys is a leading biomedical company focused
on addressing significant unmet needs of women worldwide with a
broad portfolio of in-office, accessible, and innovative
therapeutic and diagnostic solutions, including a lead
revolutionary product candidate and FDA-cleared products.
FemaSeed® Intratubal Insemination, an innovative infertility
treatment designed to deliver sperm directly where conception
occurs, is FDA-cleared and has received regulatory approval in
Canada and Europe. FemBloc® permanent birth control in
late-stage clinical development is the first and only non-surgical,
in-office, permanent birth control method intended to be a safer
option for women at substantially less cost than the long-standing
surgical alternative. The Company has developed diagnostic products
that are complementary for which it has achieved regulatory
approvals to market in the U.S., Canada, Europe, and other ex-U.S.
territories, and which are commercial-ready due to its in-house
manufacturing capabilities. Its diagnostic products include
FemVue® and FemVue® Mini for fallopian tube assessment by
ultrasound, which can be used in conjunction with FemCath®, an
intrauterine catheter for selective fallopian tube evaluation, and
FemCerv®, an endocervical tissue sampler for cervical cancer
diagnosis. Learn more at www.femasys.com, or follow us on X,
Facebook and LinkedIn.
Forward-Looking
Statements
This press release contains forward-looking
statements that are subject to substantial risks and uncertainties.
Forward-looking statements can be identified by terms such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or
“continue” or the negative of these terms or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on our current
expectations and are subject to inherent uncertainties, risks and
assumptions, many of which are beyond our control, difficult to
predict and could cause actual results to differ materially from
what we expect. Further, certain forward-looking statements are
based on assumptions as to future events that may not prove to be
accurate. Factors that could cause actual results to differ
include, among others: our ability to develop and advance our
current product candidates and programs into, and successfully
initiate, enroll and complete, clinical trials; the ability of our
clinical trials to demonstrate safety and effectiveness of our
product candidates and other positive results; estimates regarding
the total addressable market for our products and product
candidates; our ability to commercialize our products and product
candidates, or the effect of delays in commercializing our
products, including FemaSeed; our business model and strategic
plans for our products, technologies and business, including our
implementation thereof; and those other risks and uncertainties
described in the section titled "Risk Factors" in our Annual Report
on Form 10-K for the year ended December 31, 2023, and other
reports as filed with the SEC. Forward-looking statements contained
in this press release are made as of this date, and Femasys
undertakes no duty to update such information except as required
under applicable law.
Contacts:
Investors: Matt BlazeiIR@femasys.com
Media:Kati WaldenburgMedia@femasys.com
Femasys (NASDAQ:FEMY)
Historical Stock Chart
From Nov 2024 to Dec 2024
Femasys (NASDAQ:FEMY)
Historical Stock Chart
From Dec 2023 to Dec 2024